Theranos had developed proprietary technology for comprehensive blood tests from tiny samples.
Theranos, founded by Elizabeth Holmes in 2003, claimed to have developed revolutionary technology that could run 200+ blood tests from just a few drops of blood from a finger prick. The company grew to a $9 billion valuation and Holmes became celebrated as a young tech visionary. However, extensive investigations by Wall Street Journal reporter John Carreyrou revealed that the technology largely didn't work as claimed. Most Theranos tests were run on commercial lab equipment from other manufacturers, not proprietary devices. The company used unreliable methodology and provided inaccurate results to patients and doctors. Patients received wrong diagnoses and unnecessary treatments based on faulty Theranos results. In 2015-2016, Theranos voided nearly two years of blood test results. Holmes and former COO Ramesh 'Sunny' Balwani were charged with massive fraud. In 2022, Holmes was convicted and sentenced to over 11 years in prison. The Theranos scandal illustrates how charismatic entrepreneurs, venture capital hype, media attention, and regulatory gaps can enable massive fraud in healthcare technology. It also revealed the danger of insufficient regulatory oversight of laboratory-developed tests and the importance of independent verification.